https://www.livewiremarkets.com/wire...rm=READ%20MORE
"Fisher & Paykel - 10.9%
Fisher & Paykel has built multiple sustainable competitive advantages in the high-flow therapy market with its Optiflow product. These include:
Higher humidified flow rates than competitors. This allows gas in a patient's lungs to be removed and replaced with oxygen faster, therefore accelerating recovery. The tubing technology also provides better condensation management.
The generation of substantial clinical evidence using Optiflow.
An established, reputable brand, particularly in hospital ICUs.
High barriers to entry in the industry. It takes years to replicate the technology, and Fisher & Paykel continue to invest significantly in R&D which comprises a high single-digit proportion of their revenue. There is also incumbency with already installed devices."